Panhematin
Lundbeck sells $100m portfolio
January 22, 2013Sales and Marketing Lundbeck, OTC, Panhematin, Recordati
Italian pharma group Recordati has paid $80 million to Lundbeck for a portfolio of products primarily aimed at the US …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
